Firma Fresenius SE & Co. KGaA, Autor bei PR-Web

Fresenius with weak third quarter driven by ongoing challenging macroeconomic environment

Posted on 31. October 2022 by Firma Fresenius SE & Co. KGaA Posted in General Tagged cares, clinical, ebit, energy, fresenius, helios, ivenix, kabi, mabxience, market, patients, revenue, statements, vamed, with

Healthy organic sales growth and ongoing margin pressure Fresenius Medical Care’s business development impacted by delayed effects from improvements in North American Services business in challenging environment Fresenius Kabi with healthy sales growth and sequential improvement Fresenius Helios with strong […]

Fresenius Medical Care places bonds with a volume of 750 million euros

Posted on 13. September 2022 by Firma Fresenius SE & Co. KGaA Posted in General Tagged america, bonds, clinical, company, covid, financial, fresenius, kidney, market, medical, prospectus, risks, securities, statements, with

Fresenius Medical Care, the world’s leading provider of products and services for individuals with kidney diseases, today successfully placed bonds with a volume of €750 million. The bonds with a 5-year maturity and a coupon of 3.875% were issued at […]

Michael Sen to succeed Stephan Sturm as CEO of Fresenius

Posted on 22. August 2022 by Firma Fresenius SE & Co. KGaA Posted in General Tagged clinical, dynamics, energy, eon, financial, fresenius, healthineers, kabi, new, privileged, siemens, statements, strong, supervisory, with

Michael Sen (53) will become Chief Executive Officer of Fresenius on October 1, 2022. He was appointed unanimously by the Supervisory Board of Fresenius Management SE today to succeed Stephan Sturm (59), who will leave the company on good terms […]

Fresenius publishes financial results for the second quarter and first half of 2022 in line with preliminary results

Posted on 2. August 2022 by Firma Fresenius SE & Co. KGaA Posted in General Tagged currency, ebitda, energy, forma, fresenius, helios, ivenix, kabi, mabxience, market, medical, tax, treatment, vamed, with

Business development marked by significantly worsening headwinds at Fresenius Medical Care and increased macroeconomic challenges Fresenius Medical Care Business development impacted by unprecedented U.S. labor market situation and worsening macroeconomic environment Fresenius Kabi with solid organic sales growth despite tough […]

Fresenius revises FY/22 Group guidance driven by significantly worsening headwinds at Fresenius Medical Care – Outlook confirmed for Fresenius Kabi, Fresenius Helios and Fresenius Vamed

Posted on 28. July 2022 by Firma Fresenius SE & Co. KGaA Posted in General Tagged biosimilars, dialysis, ebit, ebit1, energy, fresenius, helios, ivenix, kabi, mabxience, market, patients, revenue, tax, with

Fresenius Medical Care’s financial performance in Q2/22 was significantly impacted by worsened labor shortages and related meaningfully increased wage inflation in the U.S. The further deterioration of the macro-economic environment resulted in accelerated non-wage inflation, particularly higher supply chain costs. […]

Fresenius Medical Care cuts outlook for FY 2022 due to increased headwinds from U.S. labor market and global inflation, and withdraws 2025 targets

Posted on 28. July 2022 by Firma Fresenius SE & Co. KGaA Posted in General Tagged decline, dialysis, factors, financial, fiscal, fme25, fresenius, health, home, kriwet, market, medical, new, Recovery, revenue

. – Outlook: o Revised FY 2022 targets: revenue to grow at the low end of the previously guided low to mid-single digit percentage range and net income to decline around a high teens percentage range. o Despite most burdens […]

Fresenius successfully places bonds with a volume of 1.3 billion euros

Posted on 18. May 2022 by Firma Fresenius SE & Co. KGaA Posted in General Tagged america, any, bonds, clinical, company, financial, fresenius, market, persons, prospectus, risks, securities, statements, transaction, with

Fresenius today successfully placed bonds with an aggregate volume of €1.3 billion across two tranches: • €750 million bonds with a maturity in May 2025 and an annual coupon of 1.875% and • €550 million bonds with a maturity in […]

Annual General Meeting: Fresenius remains on course for growth despite ongoing burdens; 29th consecutive dividend increase approved

Posted on 13. May 202213. May 2022 by Firma Fresenius SE & Co. KGaA Posted in General Tagged bonds, clinical, convertible, derivatives, dividend, fresenius, ice, medical, new, patients, report, statements, supervisory, tax, with

Despite ongoing burdens from the pandemic, the war in Ukraine and other external factors, the global healthcare group Fresenius remains on course for growth. This was confirmed by Stephan Sturm, CEO of Fresenius, at today’s Annual General Meeting: “We have […]

Fresenius appoints Sara Hennicken as Chief Financial Officer – Rachel Empey to leave company at own request

Posted on 4. May 20225. May 2022 by Firma Fresenius SE & Co. KGaA Posted in General Tagged Banking, clinical, company, empey, financial, fresenius, healthcare, hennicken, ive, new, risks, statements, supervisory, treasury, with

The Fresenius Management SE Supervisory Board has unanimously appointed Sara Hennicken (41), currently Senior Vice President Global Treasury & Corporate Finance at Fresenius, to become the company’s new Chief Financial Officer as of September 1, 2022. She will succeed Rachel […]

Fresenius with solid start to 2022 despite macroeconomic challenges

Posted on 4. May 20225. May 2022 by Firma Fresenius SE & Co. KGaA Posted in General Tagged ebitda, empey, financial, forma, fresenius, helios, ivenix, kabi, kriwet, mabxience, medical, strong, tax, vamed, with

. – Fresenius Medical Care in line with its expectations countering significant headwinds – Fresenius Kabi’s solid financial performance based on strong Emerging Markets growth • Fresenius Helios’ strong performance driven by growing admissions in Germany and Spain – Fresenius […]